Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. T.NVCN

Alternate Symbol(s):  NVCN

Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina.


Recent & Breaking News (TSX:NVCN)

Neovasc (TSX:NVCN) Reducer shows efficacy

Caroline Egan  12 days ago

Neovasc Provides Corporate Update Following Clinical Data Release

GlobeNewswire 12 days ago

Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

GlobeNewswire September 16, 2022

Neovasc (TSX:NVCN) comments on cew ICD-10-CM diagnosis codes for Refractory Angina

Brieanna McCutcheon  September 15, 2022

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

GlobeNewswire September 15, 2022

Neovasc Announces Key Events at TCT 2022

GlobeNewswire September 8, 2022

Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire August 30, 2022

Neovasc Announces Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2022

Neovasc to Report Second Quarter Financial Results on August 11, 2022

GlobeNewswire July 28, 2022

Neovasc (TSX:NVCN) receives FDA approval for planned COSIRA II sub-studies

Dave Jackson July 26, 2022

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

GlobeNewswire July 26, 2022

Neovasc (TSX:NVCN) announces direct sales operations in the U.K.

Dave Jackson July 5, 2022

Neovasc Announces Direct Sales Operations in United Kingdom

GlobeNewswire July 5, 2022

Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference

GlobeNewswire June 8, 2022

Neovasc to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire May 23, 2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire May 16, 2022

Neovasc Announces First Quarter Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Neovasc to Report First Quarter Financial Results on May 12, 2022

GlobeNewswire April 29, 2022

Neovasc Comments on European Heart Journal Publication

GlobeNewswire April 28, 2022

Neovasc Announces Effective Date of Share Consolidation

GlobeNewswire April 27, 2022